Next Generation Gene Therapy Vectors Summit on July 29-31, 2025 in Boston, United States

Achieve Safety through Novel Capsids and Payloads

2024 saw huge investments in gene therapy vectors. Following a $1.1 billion acquisition of Kate Therapeutics by Novartis and a collaboration between Roche and Dyno Therapeutics, which could generate more than $1 billion for Dyno, it’s time to come together and continue unlocking the ever-clearer potential of vector therapies.

The 5th Next Generation Gene Therapy Vectors Summit returns as the only vector therapy-specific platform for experts to join forces, share technical insights, transform viral and non-viral vector design and selection, and streamline translation to the clinic.

Providing an unmatched, close-knit collaborative environment created specifically with and for the gene therapy vector community, connect and learn from leaders such as Spark Therapeutics, Novartis, 4D Molecular Therapeutics, Apertura Gene Therapy, and Coave Therapeutics, in a bid to discover innovative, rational vector design and AI-driven approaches. Emphasize cost- and time-effective strategies for non-clinical testing and vector manufacturing to achieve clinical validation and deliver vector therapies to more patient populations.

URLs:

Brochure: https://go.evvnt.com/3005350-0?pid=10008

Tickets: https://go.evvnt.com/3005350-2?pid=10008

Time: 8:00 AM - 4:05 PM

Prices:

Drug Developer Conference + Workshop Day Ticket: USD 4197.00,

Drug Developer Conference Only Ticket: USD 2999.00,

Academic and Small Biotech Conference + Workshop Day Ticket: USD 3597.00,

Academic and Small Biotech Conference Only Ticket: USD 2599.00,

Solution and Service Provider Conference + Workshop Day Ticket: USD 5097.00,

Solution and Service Provider Conference Only Ticket: USD 3699.00

Speakers: Anthony Dinatale, Investment Associate, Agent Capital, Caroline Xu, Co-Founder and CEO, ViGeneron GmbH , Claudia Huichalaf, Principal Scientist, Alexion Pharma UK, Daniel Cohen, Head of Vector Optimization, Spark Therapeutics, Inc., Daniel Gao, Post-Doctoral Fellow, The Broad Institute of MIT and Harvard, Els Henckaerts, Co-Founder and Chief Scientific Officer, Tavira Therapeutics, Eric Kelsic, Co-Founder and Chief Scientific Officer, Dyno Therapeutics, Jorge Santiago-Ortiz, Senior Director, CMC, Apertura Gene Therapy, Kruti Patel, Associate Director - Adeno Associated Virus Immunology, Solid Biosciences, Leila Haery, Principal Scientist II, Novartis AG, Lolita Petit, Chief Scientific Officer, Coave Therapeutics, Lorelei Stoica, Executive Director - Nonclinical Research, Ultragenyx Pharmaceutical Inc., Ralf Schmid, Associate Director - Pre-Clinical Research, Novartis AG, Robert Lin, Chief Executive Officer, Avista Therapeutics, Roxanne Croze, Senior Director, Vector Innovation, 4D Molecular Therapeutics, Roy Levitt, MD Clinical Professor, Director, UHealth Institute for Advanced Pain Management Center, University of Miami, Samir Koirala, Head of Genetic, Neurodevelopmental and Epilepsy Disorders, Biogen, Sebastian Aguirre Kozlouski, Co-Founder, Vice President, Platform Development, Carbon Biosciences, Shashi Murthy, Chief Technology Officer, Nanite Inc., Yuan Yuan, Associate Scientific Director, Biogen